Artimplant: Artelon(R) TMC Spacer Cleared for Marketing in Canada.STOCKHOLM, Sweden -- The Swedish biomaterials company Artimplant (STO:ARTIB) receives approval to market the Artelon(R) TMC TMC Technology Marketing Corporation (Norwalk, Connecticut) TMC Texas Medical Center (Houston, TX) TMC Traffic Message Channel TMC The Movie Channel TMC Traffic Management Center Spacer in Canada. The distribution network of Small Bone Innovations will market the product. Artelon TMC Spacer for treatment of thumb base osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. Artelon TMC Spacer is an implant for treatment of thumb base osteoarthritis (OA). The Artelon Spacer is preserving the bone anatomy of the hand and is buffering the bone on bone contact that results from osteoarthritic joint degeneration. Compared to current therapy it has the following benefits; --Significantly better grip strength compared to tendon interposition in·ter·pose v. in·ter·posed, in·ter·pos·ing, in·ter·pos·es v.tr. 1. a. To insert or introduce between parts. b. To place (oneself) between others or things. 2. arthroplasty --Stable joints, no subluxations --Reduced pain --Fast and easy procedure, no general anesthesia Anesthesia, General Definition General anesthesia is the induction of a state of unconsciousness with the absence of pain sensation over the entire body, through the administration of anesthetic drugs. required --Tissue preserving approach - minimal tissue resection of the trapezial bone results in intact anatomy Successful study A pilot study with Artelon Spacer for treatment of OA in the base of the thumb conducted by Artimplant has been published in the March 2005 issue of American Journal of Hand Surgery. The results from the study show that patients with the Artelon Spacer experienced significantly better grip strength compared to a control group of patients treated with tendon interposition arthroplasty. Artelon - a unique biomaterial The Artelon TMC Spacer is made of Artelon, a unique long-term degradable de·grad·a·ble adj. That can be chemically degraded: degradable plastic wastes. de·grad biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. in hard and soft tissue - Artelon offers new solutions to unmet clinical needs in several therapy areas. Artimplant has also posted the following press releases the last six months on www.artimplant.com --Artelon(R) implant for rotator cuff reinforcement receives clearance for marketing in the USA --Artimplant receives approval to market Artelon(R) TMC Spacer in Australia --Artimplant is establishing office in the USA --Artimplant fulfils six out of seven goals of 2005 and builds distributor network within odontology odontology /odon·tol·o·gy/ (o?don-tol´ah-je) 1. scientific study of the teeth. 2. dentistry. o·don·tol·o·gy n. --Artelon(R) implant for rotator cuff reinforcement receives CE-mark --Artimplant and ArthroCare Corporation sign distribution agreement for North America --Artelon(R) nanofibers successfully used as coating on metal implants --Artimplant signs four new development and license agreements with Small Bone Innovations --Artimplant receives CE-mark for Artelon(R) Surgical Suture --Artimplant expands its long-term degradable Artelon(R) Surgical Suture product range --New study shows that Artelon(R) works as a dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. filler About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. , O-list. Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings. www.artimplant.com This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion